The Legal Arguments Plaintiffs Claim: Manufacturers (Novo Nordisk, Eli Lilly) knew or should have known about risks of gastroparesis and NAION Warning labels failed to adequately disclose these serious side effects Drugs were aggressively marketed as safe and effective weight loss solutions without proper risk disclosure Patients would not have taken the medications had they known the true risks Defendants Respond: Claims are unfounded (Novo Nordisk statement) Will defend vigorously against lawsuits Motion to dismiss expected January 24, 2025 Argue that labels were adequate and that many conditions may be pre-existing or related to diabetes itself Whos Most at Risk
Ingredient transparency matters to consumers, so we make sure our products truly deliver on it, said Sean McGrath, vice president, general manager, North America, at LLBG
# # #Reborn #Reshape # #Legacy 4 #Howtobeauty
In 2008, Rimonabant (also known as SR141716) was withdrawn from the market worldwide after being approved in 2006 due to serious psychiatric side effects that outweighed its benefits, including suicide
If I develop palpitations or a faster pulse, what symptoms should prompt immediate evaluation
From a metabolic perspective, the major advantage of MSCs lies in their pleiotropic nature
